MINNEAPOLIS, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), today announced that it will release its financial results for its third fiscal quarter ended September 30, 2025 on Wednesday, November 12, 2025, before the market opens. Vireo Growth management will host a conference call with the investment community that same day, Wednesday, November 12, 2025, at 8:30 a.m. ET (7:30 a.m. CT) to discuss its results. Interested parties may attend the confer ...

MINNEAPOLIS, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), today announced that it will release its financial results for its third fiscal quarter ended September 30, 2025 on Wednesday, November 12, 2025, before the market opens. Vireo Growth management will host a conference call with the investment community that same day, Wednesday, November 12, 2025, at 8:30 a.m. ET (7:30 a.m. CT) to discuss its results. Interested parties may attend the confer ...

Core Insights - Tilray Medical is expanding its medical cannabis operations into Panama through a joint venture with Top Tech Global Inc, which has experience in medical device distribution since 2014 [1][2] - The joint venture, named Solana Life Group, has received a medical cannabis license from the National Directorate of Pharmacy and Drugs in Panama, allowing for cultivation, manufacturing, import, export, distribution, and sale of medical cannabis [1][2] Company Overview - Tilray Medical aims to enhance patient access to medical cannabis in Panama by leveraging its global expertise alongside Top Tech's local knowledge [2] - The company is committed to supporting the Panamanian medical community through education, maintaining a reliable supply chain, and offering a comprehensive portfolio of cannabinoid-based therapies [2] - Tilray Medical has a global presence, operating in over 20 countries with a portfolio that includes various medical cannabis brands [3] Strategic Goals - The partnership with Top Tech emphasizes Tilray's dedication to patient-centric care and its mission to deliver safe, high-quality cannabis medicines tailored to individual patient needs [2] - Tilray Medical plans to collaborate with healthcare professionals, regulatory authorities, and patient advocacy organizations in Panama to provide trusted therapeutic alternatives [2]

Core Insights - Tilray's fiscal year 2025 earnings show a net revenue of $821 million, a 4% increase from the previous year, with adjustments for constant currency bringing it to $834 million [1][5] - The company is valued at a market capitalization of approximately $1.78 billion, with valuation metrics indicating it trades at a discount compared to sector medians [2] - Tilray is expanding its product offerings in Germany, launching five new cannabis products, which is seen as a strategic move to enhance its market presence [9][10] Financial Performance - The net revenue for fiscal year 2025 was $821 million, up 4% from $789 million the prior year, with a gross margin increase in the cannabis segment from 33% to 40% [1][5] - Despite a reported net loss of $2.18 billion, largely due to a non-cash impairment of goodwill, adjusted net income rose 45% to $9 million [6] - The company holds a strong liquidity position with $256 million in cash and marketable securities, having reduced its long-term debt significantly [7] Market Position and Valuation - Tilray's price-to-sales (P/S) ratio is 2.17x, compared to the sector median of 4.18x, indicating a lower valuation relative to peers [2] - The stock price is currently at $1.64, with a year-to-date increase of 21.8%, although it has seen a 52-week decline of 1.8% [3] Strategic Initiatives - The company is focusing on expanding its premium craft cannabis portfolio in Germany, which is crucial for establishing a foothold in the European market [9][10] - Recent endorsements of medical cannabis by public figures have contributed to a more optimistic outlook for the sector, potentially benefiting companies like Tilray [8] Future Outlook - Analysts estimate adjusted earnings per share for the upcoming quarters to be negative, reflecting caution regarding future profitability [11] - Management guidance indicates optimism for fiscal 2026, with expected adjusted EBITDA growth of 13% to 31% compared to fiscal 2025 [12] - The consensus among analysts is moderately bullish, with a "Moderate Buy" rating and an average price target of $1.21, suggesting a downside potential of approximately 26% [13]

Core Viewpoint - Vireo Growth Inc. is pursuing its M&A strategy by acquiring approximately 86% of the outstanding senior secured convertible notes of Medicine Man Technologies Inc. for about $62 million, payable in subordinate voting shares at a price of $0.54 per share [1][2]. Group 1: Transaction Details - The acquisition is expected to close later this month, pending customary conditions and necessary approvals [2]. - The total consideration for the Notes is approximately $62 million, which will be paid in subordinate voting shares [1]. Group 2: Company Background - Vireo Growth Inc. was founded in 2014 as a pioneering medical cannabis company, focusing on a disciplined and execution-oriented platform in the industry [3]. - The company aims to leverage its national portfolio while maintaining a strong local market focus and is committed to deploying capital and talent effectively [3].

Core Insights - Tilray Medical is expanding its Tilray Craft portfolio in Germany with five new cannabis flower products produced at its EU-GMP certified facility in Neumünster, reflecting its commitment to providing diverse, quality medical cannabis options for patients [1][2][3] Company Overview - Tilray Medical is dedicated to transforming lives by providing safe and reliable access to a global portfolio of medical cannabis brands, including Tilray Craft, and has established itself as a leading supplier of medical cannabis [5] - The company has evolved from being one of the first licensed producers of medical cannabis in Canada to building GMP-certified production facilities in Portugal and Germany [5] Product Details - The new Tilray Craft products are available by prescription at pharmacies throughout Germany, showcasing the company's dedication to advancing medical cannabis innovation and supporting healthcare professionals [3] - Tilray Craft focuses on high potency flower, cultivated indoors in Neumünster, with an emphasis on precision and quality control to ensure reliable medical cannabis for patients [4] Commitment to Quality - The production process at Tilray's facility adheres to rigorous quality control standards, ensuring that the medical cannabis provided is consistent and dependable for patient needs [2][4] - The company prioritizes patient care and aims to deliver consistent, quality solutions to physicians and pharmacies, placing patients' needs first [2]

Core Insights - Tilray Brands (NASDAQ: TLRY) has experienced a significant stock price increase of nearly 200%, rising from $0.42 in early July to $1.24, primarily due to potential reclassification of cannabis by the Trump administration from Schedule I to Schedule III [2][15] - The company is focusing on product differentiation and expanding its operations in Europe, including launching new EU-GMP certified medical cannabis strains in Germany [3] - Investors are questioning whether TLRY stock remains a compelling investment at its current price, with significant upside potential linked to the prospective reclassification of marijuana [4][16] Financial Performance - Tilray's revenues have grown at an average rate of 9.9% over the last three years, with a 4.1% increase from $789 million to $821 million in the past 12 months [12] - The latest quarterly revenues decreased by 2.3% to $225 million from $230 million a year prior [12] - The company reported an operating income of -$108 million, resulting in an operating margin of -13.1% and a cash flow margin of -11.5%, generating nearly -$95 million in operating cash flow [12] - TLRY's net income for the corresponding period was approximately -$2.2 billion, indicating a net margin of around -266.3% [12] Debt and Financial Stability - TLRY's debt stood at $329 million at the end of the most recent quarter, with a current market cap of $1.2 billion, resulting in a debt-to-equity ratio of 26.7% [13] - The company's cash (including cash equivalents) constitutes $256 million of $2.1 billion in total assets, leading to a cash-to-assets ratio of 12.4% [13] Stock Performance - TLRY stock has plummeted 97.6% from a peak of $63.91 on February 10, 2021, to $1.52 on June 23, 2023, compared to a peak-to-trough decline of 25.4% for the S&P 500 [14] - The stock has not yet rebounded to its pre-crisis peak, with the highest value since then being $3.31 on September 11, 2023, and currently trading at $1.24 [14] - TLRY stock dropped 88.4% from a high of $21.36 on January 15, 2020, to $2.47 on March 18, 2020, versus a peak-to-trough decline of 33.9% for the S&P 500 [14] Market Position and Strategy - Tilray Brands engages in the research, cultivation, production, marketing, and distribution of medical cannabis products across various segments, including GMP-certified flowers, oils, vapes, edibles, and topicals [7] - The company is enhancing its business operations by concentrating on product differentiation and developing new products for its premium segment [3]

Core Insights - InterCure Ltd. has announced the strategic acquisition of Botanico Ltd. (ISHI), enhancing its access to advanced cultivation technologies and premium American cannabis brands [1][4] - The acquisition aligns with the potential rescheduling of cannabis by the Trump administration, which could create significant opportunities for international cannabis operators like InterCure [1][4] Company Overview - InterCure is recognized as the leading and fastest-growing cannabis company outside North America, with a focus on pharmaceutical-grade medical cannabis products [7] - The company operates under the brand Canndoc and is Israel's largest licensed cannabis producer, leveraging a high-margin vertically integrated model [7] Acquisition Details - The acquisition involves a two-phase structure, with 50% of ISHI's equity acquired initially for 2,467,055 InterCure ordinary shares, and the remaining 50% contingent on ISHI achieving positive operating profitability or within 24 months [5] - The total consideration for the acquisition amounts to 4,924,261 ordinary shares, representing approximately 10% of InterCure's outstanding shares on a fully diluted basis [5] Strategic Partnerships - ISHI has established exclusive partnerships with top-tier U.S. cannabis brands, including The Flowery, which operates significant cultivation and retail facilities in Florida and New York [2] - The acquisition provides InterCure with immediate access to award-winning cannabis genetics and advanced operational technologies, enhancing its competitive position in the global medical cannabis market [2][4] Management and Operational Integration - The founders of ISHI will join InterCure's leadership team, ensuring a smooth transition and integration of operations [5][6] - The operational integration will allow for immediate access to ISHI's product supply and technology platform, supporting InterCure's expansion into international markets [5]

Core Insights - InterCure has announced the strategic acquisition of Botanico Ltd. (ISHI), enhancing its access to advanced cultivation technologies and premium American cannabis brands, coinciding with potential regulatory changes in the U.S. cannabis market [1][4] - The acquisition is expected to provide InterCure with immediate access to award-winning cannabis genetics and operational technologies, positioning the company to capitalize on evolving regulatory frameworks favoring compliant operators [2][4] Company Overview - InterCure Ltd. (dba Canndoc) is recognized as the leading and fastest-growing cannabis company outside North America, with a focus on pharmaceutical-grade medical cannabis products and a vertically integrated "seed-to-sale" model [7] Acquisition Details - The acquisition of ISHI involves a two-phase structure, with 50% of equity acquired initially for 2,467,055 InterCure ordinary shares, and the remaining 50% contingent on ISHI achieving positive operating profitability or within 24 months [5] - The total consideration for the acquisition amounts to 4,924,261 ordinary shares, representing approximately 10% of InterCure's outstanding shares on a fully diluted basis [5] Strategic Partnerships - ISHI has established exclusive partnerships with top-tier U.S. cannabis brands, including The Flowery, which operates significant cultivation and retail facilities in Florida and New York [2][6] - The acquisition is expected to enhance InterCure's supply chain and distribution operations, supporting its expansion into international markets where pharmaceutical-grade standards are becoming the benchmark [5][6] Regulatory Context - The acquisition aligns with the reported momentum in the U.S. regarding potential cannabis rescheduling, which could unlock significant opportunities for international cannabis companies like InterCure [1][4]

Board Changes - IM Cannabis Corp. announced the resignation of Messrs. Shmulik Arbel and Brian Schinderle from the Board, Audit Committee, and Compensation Committee effective September 15, 2025 [1][2] - Messrs. Asaf Yitzhaik and Eli Zamir have been appointed to the Board and the Audit Committee to fill the vacancies created by the resignations, with Mr. Zamir also joining the Compensation Committee [2] New Board Members - Mr. Yitzhaik has over three decades of experience in retail and real estate, owning ASI Glasses and holding directorships in several publicly traded companies [3] - Mr. Zamir has extensive expertise in finance and capital markets, having served as CEO of an underwriting firm and CFO of a public real estate company, and currently leads M&A and financing activities in the renewable energy sector [4] Leadership Changes - Mr. Oz Adler has been appointed as the new Chairman of the Board, replacing Mr. Oren Shuster, who remains the Chief Executive Officer and a director [5] Strategic Review - The Company is conducting an ongoing strategic review and is exploring the introduction of additional business activities to enhance long-term growth opportunities and create further shareholder value [6] Company Overview - IM Cannabis Corp. is a leading medical cannabis company operating in Israel and Germany, focusing on sustainable and profitable growth in these high-value markets [7] - The Company operates a transnational ecosystem that includes importing and distributing cannabis, retail pharmacies, online platforms, and logistical hubs in Israel, as well as distributing cannabis to pharmacies in Germany through Adjupharm GmbH [8]